Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study.

Richard B LiptonDawn C BuseClaire H SandoeJanet H FordAustin L HandJakub P JedynakMartha D Port Holland C Detke

Published in: Headache (2023)

In addition to the known efficacy of galcanezumab in the ictal period, these findings suggest treatment with galcanezumab results in a significant reduction in interictal burden.

Keyphrases

phase iii
double blind
open label
clinical trial
phase ii
risk factors
temporal lobe epilepsy